MARKET

PEPG

PEPG

PepGen Inc
NASDAQ
2.850
+0.440
+18.26%
After Hours: 2.830 -0.02 -0.70% 19:38 08/07 EDT
OPEN
2.480
PREV CLOSE
2.410
HIGH
2.875
LOW
2.440
VOLUME
3.22M
TURNOVER
--
52 WEEK HIGH
7.80
52 WEEK LOW
1.010
MARKET CAP
197.13M
P/E (TTM)
-2.1846
1D
5D
1M
3M
1Y
5Y
1D
Is PepGen (NASDAQ:PEPG) In A Good Position To Invest In Growth?
Simply Wall St · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: GoodRx Holdings (GDRX), Xencor (XNCR) and PepGen Inc. (PEPG)
TipRanks · 3d ago
PepGen Advances PGN-EDODM1 Trial and Strengthens Finances
TipRanks · 3d ago
PepGen Q2 EPS $(0.26) Beats $(0.29) Estimate
Benzinga · 3d ago
PepGen Receives Recommendation To Advance its Phase 2 FREEDOM2-DM1 Study Of PGN-EDODM1 In Participants With Myotonic Dystrophy Type 1 Into The Highest Dose Cohort
Benzinga · 3d ago
Press Release: PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Dow Jones · 3d ago
Weekly Report: what happened at PEPG last week (0727-0731)?
Weekly Report · 6d ago
PepGen: PGN-EDODM1 Multisystem Efficacy Potential Supports Buy Rating with Unchanged $20 Price Target
TipRanks · 07/31 17:15
More
About PEPG
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Webull offers PepGen Inc stock information, including NASDAQ: PEPG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEPG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PEPG stock methods without spending real money on the virtual paper trading platform.